Diagnostic value of pleural effusion Krebs von den Lungen-6 in malignant pleural effusion of patients with non-small cell lung cancer.

Laboratory medicine Pub Date : 2024-05-02 DOI:10.1093/labmed/lmad076

Junjun Wang, Liqun Ling, Shuhui Chen, Lunan Chou, Yumin Wang, Lijuan Hu

{"title":"Diagnostic value of pleural effusion Krebs von den Lungen-6 in malignant pleural effusion of patients with non-small cell lung cancer.","authors":"Junjun Wang, Liqun Ling, Shuhui Chen, Lunan Chou, Yumin Wang, Lijuan Hu","doi":"10.1093/labmed/lmad076","DOIUrl":null,"url":null,"abstract":"Objective: The aim of this study was to investigate the diagnostic potential of Krebs von den Lungen-6 (KL-6) in differentiating between malignant pleural effusion (MPE) induced by non-small cell lung cancer (NSCLC) and benign pleural effusion (BPE).Methods: We collected 143 pleural effusion samples from August 2018 to March 2021. The samples included 91 cases of MPE and 52 cases of BPE. The KL-6 and other indicators in pleural effusion were detected.Results: The level of pleural effusion KL-6 (pKL-6) in the MPE group was significantly higher than in the BPE group (Mann-Whitney U = 442.500, P = .000). The area under the curve (AUC) of pKL-6/pleural effusion adenosine deaminase (pADA) + pleural effusion carcinoembryonic antigen (pCEA)/pADA (AUC = 0.992) in diagnosing MPE was higher than that of pKL-6 alone (AUC = 0.903), with a sensitivity of 93.26% and specificity of 100%.Conclusion: The measurement of pKL-6 can differentiate NSCLC-induced MPE from BPE. Furthermore, the combined detection of pKL-6/pADA and pCEA/pADA can significantly improve the diagnostic efficiency for distinguishing NSCLC-induced MPE.","PeriodicalId":17951,"journal":{"name":"Laboratory medicine","volume":" ","pages":"271-276"},"PeriodicalIF":0.0000,"publicationDate":"2024-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Laboratory medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/labmed/lmad076","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: The aim of this study was to investigate the diagnostic potential of Krebs von den Lungen-6 (KL-6) in differentiating between malignant pleural effusion (MPE) induced by non-small cell lung cancer (NSCLC) and benign pleural effusion (BPE).

Methods: We collected 143 pleural effusion samples from August 2018 to March 2021. The samples included 91 cases of MPE and 52 cases of BPE. The KL-6 and other indicators in pleural effusion were detected.

Results: The level of pleural effusion KL-6 (pKL-6) in the MPE group was significantly higher than in the BPE group (Mann-Whitney U = 442.500, P = .000). The area under the curve (AUC) of pKL-6/pleural effusion adenosine deaminase (pADA) + pleural effusion carcinoembryonic antigen (pCEA)/pADA (AUC = 0.992) in diagnosing MPE was higher than that of pKL-6 alone (AUC = 0.903), with a sensitivity of 93.26% and specificity of 100%.

Conclusion: The measurement of pKL-6 can differentiate NSCLC-induced MPE from BPE. Furthermore, the combined detection of pKL-6/pADA and pCEA/pADA can significantly improve the diagnostic efficiency for distinguishing NSCLC-induced MPE.

查看原文本刊更多论文

Krebs-von den Lungen-6胸腔积液对癌症恶性胸腔积液的诊断价值。

目的：探讨Krebs-von den Lungen-6（KL-6）对癌症（NSCLC）引起的恶性胸腔积液（MPE）和良性胸腔积液（BPE）的鉴别诊断价值。方法：我们收集了2018年8月至2021年3月的143份胸腔积液样本。样本包括91例MPE和52例BPE。检测胸腔积液KL-6等指标。结果：MPE组胸腔积液KL-6（pKL-6）水平显著高于BPE组（Mann-Whitney U=442.500，P=0.000）。pKL-6/胸腔积液腺苷脱氨酶（pADA）+胸腔积液癌胚抗原（pCEA）/pADA的曲线下面积（AUC）（AUC=0.992）诊断MPE高于单独的pKL-6（AUC=0.0903），敏感性为93.26%，特异性为100%。结论：pKL-6的测定可以区分NSCLC诱导的MPE和BPE。此外，pKL-6/pADA和pCEA/pADA的联合检测可以显著提高区分NSCLC诱导的MPE的诊断效率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Laboratory medicine

自引率

0.00%

发文量